Form 8-K - Current report:
SEC Accession No. 0001171843-25-002980
Filing Date
2025-05-08
Accepted
2025-05-08 16:01:36
Documents
15
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_050825.htm   iXBRL 8-K 14918
2 PRESS RELEASE exh_991.htm EX-99.1 52514
  Complete submission text file 0001171843-25-002980.txt   274591

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3003
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25598
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
17 EXTRACTED XBRL INSTANCE DOCUMENT f8k_050825_htm.xml XML 3336
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 25925821
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)